Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European…
Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a…
GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced…
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1…
MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss…
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or…
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…
For the first time ever, women across the U.S. have access to a comfortable, convenient, and accurate at-home cervical cancer…
In this free webinar, learn how modeling and simulation can help navigate the Animal Rule in drug development. Attendees will…